Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
暂无分享,去创建一个
B. Quesnel | P. Hérait | A. Stathis | D. Cunningham | C. Kahatt | M. Riveiro | Elodie Odore | M. Bekradda | E. Cvitkovic | F. Lokiec | F. Bourdel | E. Raffoux | C. Thieblemont | K. Rezaï | M. Békradda
[1] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[2] F. Westermann,et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.
[3] A. Palumbo,et al. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies , 2014 .
[4] P. Hérait,et al. Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples , 2014 .
[5] G. Inghirami,et al. Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma , 2014 .
[6] H. Dombret,et al. Abstract LB-231: A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies , 2014 .
[7] M. White-Koning,et al. Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients , 2014, Investigational New Drugs.
[8] J. Noel,et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .
[9] Travis J Cohoon,et al. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[10] Reid C Thompson,et al. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.
[11] J. Bradner,et al. Small-molecule inhibition of BRD 4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia ( AML ) , 2013 .
[12] J. Bradner,et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) , 2012, Oncotarget.
[13] Ming-Ming Zhou,et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. , 2012, The Journal of Biological Chemistry.
[14] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[15] Ming-Ming Zhou,et al. Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition* , 2012, The Journal of Biological Chemistry.
[16] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[17] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[18] Marc Lavielle,et al. Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..
[19] Michel Struys,et al. Pharmacokinetics in obese patients , 2004 .
[20] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] France Mentré,et al. The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.
[22] J. Wagner,et al. History of pharmacokinetics. , 1981, Pharmacology & therapeutics.